




<rss xmlns:a10="http://www.w3.org/2005/Atom" version="2.0">
    <channel>
        <title>Invasive Cardiovascular Angiography and Intervention</title>
        <link>http://www.acc.org/Feed?clinicalTopicID=2d1edb86-1b6a-4771-8577-42769c4272ef</link>
        <description>Clinical Topic Feed: Invasive Cardiovascular Angiography and Intervention</description>
        <language>en</language>

        

                <item>
                    <title>Mechanical Leaflet Splitting is Feasible in High-Risk Patients Undergoing Valve-in-Valve TAVR</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/07/07/13/29/Mechanical-Leaflet-Splitting</link>                    <description>Mechanical leaflet splitting in patients with anatomically high-risk undergoing valve-in-valve (ViV) TAVR saw high procedural success, according to a study published June 25 in JACC: Cardiovascular Interventions.</description>
                    <pubdate>1783448340000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Eagle&#226;€™s Eye View: Clopidogrel vs. Aspirin Following PCI</title>
<link>/Latest-in-Cardiology/Articles/2026/07/01/12/47/eagles-eye-view-01jul2026</link>                    <description>In this week&#226;€™s View, Dr. Eagle looks at how genotype independently predicts heart failure outcomes in patients with hypertrophic cardiomyopathy (HCM).</description>
                    <pubdate>1782910140000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Cutting-Edge Structural Interventions | Transcatheter Treatment of Mitral Annular Calcification: Where Do We Stand?</title>
<link>/Latest-in-Cardiology/Articles/2026/07/01/01/Cutting-Edge-Structural-Interventions</link>                    <description>Mitral annular calcification (MAC), which can produce mitral regurgitation (MR), mitral stenosis or both, is among the most challenging conditions to manage in cardiovascular medicine due to anatomic and patient complexity.</description>
                    <pubdate>1782908160000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Online Exclusive | SCAI 2026 Roundup: Major Coronary, Structural and Vascular Trials From Montr&#195;&#169;al</title>
<link>/Latest-in-Cardiology/Articles/2026/07/01/01/Online-Exclusive-SCAI-2026-Roundup</link>                    <description>The 2026 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions and CAIC-ACCI Summit, held in Montr&#195;&#169;al, Canada, highlighted the continuing evolution of interventional cardiology through the presentation of several important late-breaking clinical trials.</description>
                    <pubdate>1782908100000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>JACC in a Flash | Consistent Renal Benefit With Semaglutide in T2D/CKD; Late Pericardial Effusion Post LAAO</title>
<link>/Latest-in-Cardiology/Articles/2026/07/01/01/JACC-in-a-Flash</link>                    <description>Featured topics and Editors&#39; Picks from all of ACC&#39;s JACC Journals.</description>
                    <pubdate>1782907800000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>NY Valves 2026 Spotlights Redo-TAVR Strategies; Aortic Leaflet Modification Asia-Pacific Data</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/06/29/15/38/NY-Valves-2026</link>                    <description>To help address the growing challenge of structural valve deterioration following TAVR, the international, multidisciplinary Heart and Valve Collaboratory has released consensus-based procedural workflows for re-do TAVR.</description>
                    <pubdate>1782905400000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>ACC Featured Jobs For July 2026</title>
<link>/Latest-in-Cardiology/Articles/2022/01/01/01/01/ACC-Featured-Jobs</link>                    <description>Ready to explore a new professional opportunity? Browse the list below of featured jobs and take the next step in your career!</description>
                    <pubdate>1782902880000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>PARTNER 3: 7-Year Follow-Up Shows TAVR and Surgery Comparable in Low-Risk Patients With Symptomatic Severe AS</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/06/29/15/38/PARTNER-3</link>                    <description>TAVR and surgery demonstrated comparable and sustained valve durability in low-risk patients with symptomatic severe aortic stenosis (AS), with both approaches showing low and similar rates of structural valve deterioration (SVD), all-cause bioprosthetic valve failure (BVF) and reintervention through seven years...</description>
                    <pubdate>1782845400000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>Clopidogrel May Offer Long-Term Edge Over Aspirin After PCI</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/06/23/13/25/Clopidogrel-May-Offer-Long-Term-Edge</link>                    <description>Clopidogrel monotherapy was associated with lower risks of major adverse cardiovascular events (MACE) and major bleeding compared with aspirin monotherapy among stable patients post PCI, according to a nationwide cohort study published June 15 in JACC: Asia.</description>
                    <pubdate>1782399720000</pubdate>
                    <category>Articles and Stories</category>
                </item>
                <item>
                    <title>PARTNER 2A, P2S3i Registry: 10-Year TAVR Outcomes With SAPIEN XT, SAPIEN 3</title>
<link>/Latest-in-Cardiology/Journal-Scans/2026/06/23/13/25/PARTNER-2A-P2S3i-Registry</link>                    <description>The rates of mortality and reintervention at 10 years were higher in patients at intermediate risk who underwent TAVR with the second-generation SAPIEN XT valve than those who underwent surgery in the PARTNER 2A trial, according to an analysis published June 16 in a valvular heart disease focus issue of JACC.</description>
                    <pubdate>1782399420000</pubdate>
                    <category>Articles and Stories</category>
                </item>

    </channel>
</rss>